Medicus Pharma Raises $14M to Fund AI-Driven Pipeline Ahead of Phase 2 Catalyst
Medicus Pharma’s leadership has invested $14 million of personal capital at $4 per share to advance its drug pipeline and is leveraging AI to accelerate development. The company expects Phase 2 clinical readouts for SkinJect skin cancer treatment in the first half of 2026, aiming to shift investor sentiment.
1. Live CEO Interview
On February 10, CEO Dr. Raza Bokhari participated in a live global broadcast discussing Medicus Pharma’s strategic focus, market volatility in biotech, and expected regulatory optionality.
2. Leadership Capital Commitment
The executive team has invested nearly $14 million of personal capital at $4 per share, underscoring their confidence in advancing the company’s novel therapeutic pipeline.
3. AI-Driven Development Approach
Dr. Bokhari outlined how proprietary artificial intelligence tools are being leveraged to accelerate preclinical and clinical programs, aiming to streamline target identification and trial design.
4. Phase 2 SkinJect Catalyst
Medicus Pharma anticipates Phase 2 clinical data for its SkinJect skin cancer treatment in the first half of 2026, which management believes could materially shift investor perception.